Miflonide Breezhaler (Budesonide)

Budesonide binds to glucocorticoid receptors inside airway cells, altering gene expression to suppress the release of inflammatory mediators. This reduces swelling, mucus production, and the activity of immune cells in the lungs, leading to improved airflow and fewer asthma or COPD exacerbations.

The dose of Miflonide Breezhaler is individualized by the prescribing healthcare professional based on the severity of the disease, patient age, and response to therapy. Patients should follow the specific instructions provided by their prescriber and not adjust the dose without medical guidance.

Safety data for budesonide inhalation in pregnancy and lactation are limited. The medication should only be used if the potential benefit to the mother outweighs any possible risk to the fetus or infant. Women who are pregnant, planning pregnancy, or breastfeeding should discuss use with their healthcare provider.

To request Miflonide Breezhaler, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements), and the necessary import documentation.

Miflonide Breezhaler delivers budesonide, which has a high topical potency and low systemic bioavailability compared with some alternatives such as fluticasone propionate. Both agents reduce airway inflammation, but budesonide may have a slightly faster onset of action and a different inhaler device, which can influence patient preference and adherence.

Store the inhaler at room temperature, below 25 °C, in its original packaging to protect it from moisture and direct sunlight. Keep the device out of reach of children and avoid exposing it to extreme temperatures, which could affect the powder’s integrity and dosing accuracy.

Miflonide Breezhaler is a dry‑powder inhaler. The patient should exhale fully away from the device, place the mouthpiece in the mouth, seal lips tightly, and inhale sharply and deeply through the inhaler. After inhalation, the patient should hold their breath for about 10 seconds, then exhale slowly. The device should be cleaned according to the manufacturer’s instructions.

Serious risks include paradoxical bronchospasm, which can worsen breathing immediately after use, and systemic effects such as adrenal suppression when high doses are used long‑term. Rare but severe reactions may involve pneumonia, severe allergic responses (anaphylaxis), and growth suppression in children. Patients should be monitored for these events and instructed to seek medical help promptly if they occur.

Miflonide Breezhaler is contraindicated in individuals with a known hypersensitivity to budesonide or any component of the inhaler. It should also be avoided in patients with untreated active infections of the respiratory tract, including tuberculosis, until the infection is adequately treated. Clinicians must evaluate each patient’s medical history before initiating therapy.